By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.

Key Statistics

Ownership: Public

Web Site: Dynavax
Symbol: DVAX

Company News
Dynavax (DVAX) To Present At Upcoming Investor Conferences 9/5/2017 11:47:10 AM
Dynavax (DVAX) Announces Exercise In Full Of Over-Allotment Option And Completion Of Public Offering Of Common Stock 8/16/2017 8:59:11 AM
Dynavax (DVAX) Announces Proposed Public Offering Of Common Stock 8/9/2017 11:30:53 AM
Dynavax (DVAX) Shares Plunge on Delayed FDA Decision for Hep B Vaccine Heplisav 8/4/2017 6:42:49 AM
Dynavax (DVAX) Reports Second Quarter 2017 Financial Results 8/2/2017 11:05:30 AM
FDA Panel Votes to Recommend Dynavax (DVAX)'s Hepatitis B Vaccine; Hepsilav Can Compete With GlaxoSmithKline (GSK)'s Engerix-B 7/31/2017 6:21:21 AM
Death Count Rises for Patients on Dynavax (DVAX)'s Hep B Vaccine But Overall Rate Was Low, Says the FDA 7/26/2017 7:02:52 AM
Dynavax (DVAX) To Present Data On SD-101 In Combination With KEYTRUDA At The 2017 ASCO Annual Meeting 5/19/2017 9:07:10 AM
Dynavax (DVAX) Reports First Quarter 2017 Financial Results 5/8/2017 9:39:27 AM
Dynavax (DVAX) Announces FDA Advisory Committee Meeting To Review HEPLISAV-B 4/3/2017 11:02:59 AM